23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › SUTRO BIOPHARMA INC. › 2023-2024

SUTRO BIOPHARMA INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and SUTRO BIOPHARMA INC.’s Form 8-K, filed June 10, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 144Asset managers, any item
  • 895Fund votes
  • June 6, 2024Meeting date

Results at a glance

Meeting of June 6, 2024: 5 items on SUTRO BIOPHARMA INC.’s Form 8-K, filed June 10, 2024: 5 passed (calculated).

Dissent

Significant dissent: 1 director (34.5% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Ra Capital Management, L.P. (13F, 1.3%, as of September 30, 2026)

Explore SUTRO BIOPHARMA INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by SUTRO BIOPHARMA INC.

These tallies are SUTRO BIOPHARMA INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 10, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

SUTRO BIOPHARMA INC. — official shareholder meeting results, meeting held June 6, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Joseph M. Lobacki 49,578,870---- 1,393,86313,906,799 97%Passed (calculated)—
Elect Director: Daniel H. Petree 33,386,033---- 17,586,70013,906,799 65%Passed (calculated)—
2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 64,598,771118,896161,865 ---- 99.8%Passed (calculated)—
3. Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers 50,214,198171,189587,346 --13,906,799 99.7%Passed (calculated)—
4. Approval of the amendment of the Company's 2018 Employee Stock Purchase Plan (the " ESPP ") to (i) increase the overall limit on the number of shares that may be issued under the ESPP throughout its ten-year term, and (ii) make certain non-substantive clari 50,224,587618,712129,434 --13,906,799 99%Passed (calculated)—

Source: SUTRO BIOPHARMA INC., Form 8-K, filed with the SEC on June 10, 2024 — read the filing on EDGAR.

How asset managers voted at the SUTRO BIOPHARMA INC. 2023-2024 meeting

144 asset managers disclosed a vote on at least one SUTRO BIOPHARMA INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Daniel H. Petree

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

65% Majority: yes · of votes cast

FOR 65%WITHHELD
FOR: 33,386,033WITHHELD: 17,586,700
Details: description as filed, official tally, votes by 51 asset managers

Description as filed by funds: Election of Class III Directors: Daniel H. Petree

SUTRO BIOPHARMA INC.’s own tally for this item (“Elect Director: Daniel H. Petree”): 33,386,033 for, 17,586,700 withheld, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 65% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 51 asset managers below reported 7,895,863 for, 2,282,950 withheld, 152,276 abstained.

FORWITHHOLD
FOR: 7,895,863ABSTAIN: 152,276WITHHOLD: 2,282,950
Largest asset managers voting on “Election of Class III Directors: Daniel H. Petree” at SUTRO BIOPHARMA INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard2,983,1340 00For
BlackRock2,633,8090 00For
Fidelity1,338,9000 0500For
Dimensional00 0792,430Withhold
Goldman Sachs00 0505,154Withhold
TIAA434,9550 00For
Equitable108,7160 075,300Mixed
Nationwide9410 0164,047Withhold
Charles Schwab160,8760 00For
Columbia Threadneedle00 0149,005Withhold
BRIDGEWAY FUNDS INC00 0145,200Withhold
QUANTITATIVE MASTER SERIES LLC113,7020 00For
American Century00 074,398Withhold
ETF Series Solutions00 71,5770Abstain
Aberdeen00 069,389Withhold
Lincoln Financial1,7020 052,178Withhold
GuideStone00 048,744Withhold
Russell Investments30,9280 00For
AIG/SunAmerica00 030,740Withhold
John Hancock00 27,5120Abstain
Northern Trust00 027,332Withhold
Bridge Builder Trust24,1110 00For
Pacific Life23,4210 00For
State Street00 022,601Withhold
Voya00 022,229Withhold

Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).

Elect Director: Joseph M. Lobacki

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 49,578,870WITHHELD: 1,393,863
Details: description as filed, official tally, votes by 51 asset managers

Description as filed by funds: Election of Class III Directors: Joseph M. Lobacki

SUTRO BIOPHARMA INC.’s own tally for this item (“Elect Director: Joseph M. Lobacki”): 49,578,870 for, 1,393,863 withheld, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 51 asset managers below reported 9,427,765 for, 883,935 withheld, 19,389 abstained.

FOR
FOR: 9,427,765ABSTAIN: 19,389WITHHOLD: 883,935
Largest asset managers voting on “Election of Class III Directors: Joseph M. Lobacki” at SUTRO BIOPHARMA INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard2,983,1340 00For
BlackRock2,633,8090 00For
Fidelity1,339,4000 00For
Dimensional00 0792,430Withhold
Goldman Sachs505,1540 00For
TIAA434,9550 00For
Equitable108,7160 075,300Mixed
Nationwide164,9880 00For
Charles Schwab160,8760 00For
Columbia Threadneedle149,0050 00For
BRIDGEWAY FUNDS INC145,2000 00For
QUANTITATIVE MASTER SERIES LLC113,7020 00For
American Century74,3980 00For
ETF Series Solutions71,5770 00For
Aberdeen69,3890 00For
Lincoln Financial51,8020 02,078For
GuideStone48,7440 00For
Russell Investments30,9280 00For
AIG/SunAmerica30,7400 00For
John Hancock25,7470 1,7650Mixed
Northern Trust27,3320 00For
Bridge Builder Trust24,1110 00For
Pacific Life23,4210 00For
State Street22,6010 00For
Voya22,2290 00For

Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).

Approval of the amendment of the Company's 2018 Employee Stock Purchase Plan (the " ESPP ") to (i) increase the overall…

Calculated outcomeFund totals may overlapCOMPENSATIONPassed (calculated)

Combines 7 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 50,224,587AGAINST: 618,712
Details: description as filed, official tally, votes by 56 asset managers

Description as filed by funds: To approve the amendment of our 2018 Employee Stock Purchase Plan (the "ESPP") to (i) increase the overall limit on the number of shares that may be issued under our ESPP throughout its ten-year term, and (ii) make certain non-substantive clarifying revisions.

SUTRO BIOPHARMA INC.’s own tally for this item (“4. Approval of the amendment of the Company's 2018 Employee Stock Purchase Plan (the " ESPP ") to (i) increase the overall limit on the number of shares that may be issued under the ESPP throughout its ten-year term, and”): 50,224,587 for, 618,712 against, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 52 asset managers voting on “To approve the amendment of our 2018 Employee Stock Purchase Plan (the "ESPP") to (i) increase the overall lim” at SUTRO BIOPHARMA INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard2,983,1340 00For
BlackRock2,633,8090 00For
Fidelity1,339,4000 00For
Dimensional792,4300 00For
Goldman Sachs505,1540 00For
TIAA434,9550 00For
Equitable184,0160 00For
Nationwide164,047941 00For
Charles Schwab0160,876 00Against
Columbia Threadneedle149,0050 00For
BRIDGEWAY FUNDS INC145,2000 00For
Simplify Exchange Traded Funds00 0120,000Withhold
QUANTITATIVE MASTER SERIES LLC113,7020 00For
American Century74,3980 00For
ETF Series Solutions71,5770 00For
Aberdeen69,3890 00For
Lincoln Financial53,8800 00For
GuideStone48,7440 00For
Russell Investments030,928 00Against
AIG/SunAmerica30,7400 00For
John Hancock27,5120 00For
Northern Trust27,3320 00For
Bridge Builder Trust24,1110 00For
Pacific Life23,4210 00For
State Street22,6010 00For

Fund voting reports, all 52 managers: 10,097,161 for, 233,928 against, 120,000 withheld. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 4 asset managers voting on “To approve the amendment of our 2018 Employee Stock Purchase Plan (the "ESPP") to (i) increase the overall lim” at SUTRO BIOPHARMA INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Kynam Capital Management, LP00 01,892,497Withhold
Eversept Partners, LP1,488,8280 00For
ALGERT GLOBAL LLC023,761 00Against
Empirical Financial Services, LLC d.b.a. Empirical Wealth Ma01,372 00Against

Institutional-manager reports, all 4 managers: 1,488,828 for, 25,133 against, 1,892,497 withheld.

Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 6 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%
FOR: 50,214,198AGAINST: 171,189

Prior year: 80.7% for (June 8, 2023 meeting) ▲ 19.0 pts

Details: description as filed, official tally, votes by 143 asset managers

Description as filed by funds: TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.

SUTRO BIOPHARMA INC.’s own tally for this item (“3. Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers”): 50,214,198 for, 171,189 against, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 52 asset managers voting on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.” at SUTRO BIOPHARMA INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard2,983,1340 00For
BlackRock2,633,8090 00For
Fidelity1,339,4000 00For
Dimensional792,4300 00For
Goldman Sachs505,1540 00For
TIAA434,9550 00For
Equitable184,0160 00For
Nationwide164,9880 00For
Charles Schwab160,8760 00For
Columbia Threadneedle149,0050 00For
BRIDGEWAY FUNDS INC145,2000 00For
Simplify Exchange Traded Funds00 0120,000Withhold
QUANTITATIVE MASTER SERIES LLC113,7020 00For
American Century74,3980 00For
ETF Series Solutions71,5770 00For
Aberdeen69,3890 00For
Lincoln Financial53,8800 00For
GuideStone48,7440 00For
Russell Investments30,9280 00For
AIG/SunAmerica30,7400 00For
John Hancock27,5120 00For
Northern Trust27,3320 00For
Bridge Builder Trust24,1110 00For
Pacific Life23,4210 00For
State Street22,6010 00For

Fund voting reports, all 52 managers: 10,309,827 for, 8,043 against, 120,000 withheld, 13,219 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 110 asset managers voting on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.” at SUTRO BIOPHARMA INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
SUVRETTA CAPITAL MANAGEMENT, LLC7,608,6820 00For
Point725,847,6860 00For
MPM BioImpact LLC4,121,2080 00For
BlackRock2,305,6070 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.2,241,6290 00For
Kynam Capital Management, LP00 01,892,497Withhold
BAILLIE GIFFORD & CO LTD1,793,1540 00For
Eversept Partners, LP1,488,8280 00For
GEODE CAPITAL MANAGEMENT, LLC1,305,4680 00For
Samsara BioCapital, LLC1,271,2350 00For
State Street1,109,1500 00For
Two Sigma1,071,0640 00For
Aquilo Capital Management, LLC987,3960 00For
JACOBS LEVY EQUITY MANAGEMENT, INC587,7760 00For
PANAGORA ASSET MANAGEMENT INC530,4780 00For
Ensign Peak Advisors, Inc481,5090 00For
Candriam S.C.A.00 440,3690Abstain
Nuveen438,5380 00For
ACADIAN ASSET MANAGEMENT LLC427,2620 00For
Renaissance370,4070 00For
DAFNA Capital Management LLC334,0790 00For
DE Shaw296,9830 00For
UBS275,0570 00For
Northern Trust271,5560 00For
Hudson Bay Capital Management LP269,4860 00For

Institutional-manager reports, all 110 managers: 38,148,356 for, 102,693 against, 1,892,497 withheld, 440,369 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%
FOR: 64,598,771AGAINST: 118,896

Prior year: 99.9% for (June 8, 2023 meeting) ▼ 0.1 pts

Details: description as filed, official tally, votes by 52 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2024.

SUTRO BIOPHARMA INC.’s own tally for this item (“2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024”): 64,598,771 for, 118,896 against, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 10,317,705 for, 165 against, 120,000 withheld, 13,219 abstained.

FOR
FOR: 10,317,705AGAINST: 165ABSTAIN: 13,219WITHHOLD: 120,000
Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FI” at SUTRO BIOPHARMA INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard2,983,1340 00For
BlackRock2,633,8090 00For
Fidelity1,339,4000 00For
Dimensional792,4300 00For
Goldman Sachs505,1540 00For
TIAA434,9550 00For
Equitable184,0160 00For
Nationwide164,9880 00For
Charles Schwab160,8760 00For
Columbia Threadneedle149,0050 00For
BRIDGEWAY FUNDS INC145,2000 00For
Simplify Exchange Traded Funds00 0120,000Withhold
QUANTITATIVE MASTER SERIES LLC113,7020 00For
American Century74,3980 00For
ETF Series Solutions71,5770 00For
Aberdeen69,3890 00For
Lincoln Financial53,8800 00For
GuideStone48,7440 00For
Russell Investments30,9280 00For
AIG/SunAmerica30,7400 00For
John Hancock27,5120 00For
Northern Trust27,3320 00For
Bridge Builder Trust24,1110 00For
Pacific Life23,4210 00For
State Street22,6010 00For

Showing the 25 largest of 52 asset managers. All 52 are in the interactive database (link above).

Largest SUTRO BIOPHARMA INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 81,794,334 shares outstanding at the time of that meeting.

Fund voting reports: top SUTRO BIOPHARMA INC. shareholders by shares voted on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 3.65%
2BlackRock 3.22%
3Fidelity 1.64%
4Dimensional 0.97%
5Goldman Sachs 0.62%
6TIAA 0.53%
7Equitable 0.22%
8Nationwide 0.20%
9Charles Schwab 0.20%
10Columbia Threadneedle 0.18%
Institutional-manager reports: top SUTRO BIOPHARMA INC. shareholders by shares voted on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.”, 2023-2024
#Asset manager % of shares outstanding
1SUVRETTA CAPITAL MANAGEMENT, LLC 9.30%
2Point72 7.15%
3MPM BioImpact LLC 5.04%
4BlackRock 2.82%
5ADAGE CAPITAL PARTNERS GP, L.L.C. 2.74%
6Kynam Capital Management, LP 2.31%
7BAILLIE GIFFORD & CO LTD 2.19%
8Eversept Partners, LP 1.82%
9GEODE CAPITAL MANAGEMENT, LLC 1.60%
10Samsara BioCapital, LLC 1.55%

Reported SUTRO BIOPHARMA INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

SUTRO BIOPHARMA INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
S5,778,188 7.06%Schedule 13G, filed February 13, 2024
Suvretta Capital Management, LLC5,778,188 7.06%Proxy statement (DEF 14A), proxy filed April 26, 2024
Adage Capital Partners GP, LLC4,467,796 5.46%Proxy statement (DEF 14A), proxy filed April 26, 2024
Vanguard Group3,682,986 4.50%Form 13F, quarter ended March 31, 2024
Integrated Core Strategies (US) LLC3,451,825 4.22%Proxy statement (DEF 14A), proxy filed April 26, 2024
BVF Inc.3,347,946 4.09%Proxy statement (DEF 14A), proxy filed April 26, 2024
Rubric Capital Management LP3,344,810 4.09%Proxy statement (DEF 14A), proxy filed April 26, 2024
William J. Newell1,726,068 2.11%Proxy statement (DEF 14A), proxy filed April 26, 2024
BlackRock1,687,880 2.06%Form 13F, quarter ended March 31, 2024
Dimensional Fund Advisors1,308,884 1.60%Form 13F, quarter ended March 31, 2024

Percentages above are of 81,794,334 shares outstanding, as reported by SUTRO BIOPHARMA INC. on its Form 10-Q dated May 8, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At SUTRO BIOPHARMA INC.'s shareholder meeting held June 6, 2024, in the 2023-2024 proxy season, 144 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 895 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. — FOR was 99.7% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: SUTRO BIOPHARMA INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 10, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from SUTRO BIOPHARMA INC.’s 10-Q dated May 8, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

SUTRO BIOPHARMA INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “SUTRO BIOPHARMA (STRO) 2024 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/sutro-biopharma-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.